Photo taken from Manni Mohyuddin/X
Feb 23, 2024, 14:39
Manni Mohyuddin: Why striving for MRD negativity at all costs and having MRD as a primary endpoint may not be ideal
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared on X/Twitter:
“Why striving for MRD negativity at all costs and having MRD as a primary endpoint may not be ideal:
In this randomized three-arm trial, the arm with the best MRD negativity rate had the worst overall survival!
One of the most important take-home messages from ASH23!
The pursuit of MRD negativity is neither necessary, nor safe for a substantial proportion of (older/less fit) patients with multiple myeloma, who experience prolonged disease control/excellent quality of life with lesser levels of response.
This is a fact that is often omitted from the discussion. Link to study.”
Source: Manni Mohyuddin/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 31, 2024, 00:35
Oct 30, 2024, 23:46
Oct 30, 2024, 20:43
Oct 30, 2024, 20:43